WELCOME TO THE NEXT ADDITION OF THE EDRA NEWSLETTER!

In what has been a challenging last 12 months, the EDRA team have been working throughout the COVID-19 pandemic (socially distant of course) to deliver the project. Below is an update of the project so far...

TRIBUTE TO DR JOHN TIMMS

It is with great sadness that we announce that Dr John Timms passed away on 7th January 2021. John was an Associate Professor of cancer proteomics at UCL and leader of Work Package 2, in partnership with Professor Justin Hsuan. He was a brilliant colleague and dear friend. He will be missed and our thoughts and condolences go out to John’s family and friends.

EXTENSION TO THE EDRA PROJECT

Due to the on-going impact of the COVID-19 pandemic, the EDRA project has officially been extended until 30 April 2022. We are now 29 months through the project:

---

<table>
<thead>
<tr>
<th>Month</th>
<th>12</th>
<th>24</th>
<th>36</th>
<th>42</th>
</tr>
</thead>
<tbody>
<tr>
<td>WP1</td>
<td>Qifresearch case:control study (University of Oxford)</td>
<td>CPrID case:control study (UCL)</td>
<td>Symptom Cancer Decision Support Tool (CDSST) refinement</td>
<td>Validation in WP3</td>
</tr>
<tr>
<td>WP2</td>
<td>PDAC/PNET biomarker optimisation</td>
<td>Serum biomarker validation for PDAC/PNETs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WP3</td>
<td>Establishment of multicentre biobank of collected samples from symptomatic patients with suspected PDAC</td>
<td>Follow up of patients with banked samples</td>
<td>Pilot Implementation of CDSST + blood biomarker panel</td>
<td></td>
</tr>
<tr>
<td>WP4</td>
<td>WP 4 Literature Review</td>
<td>Stakeholder analysis &amp; health economics</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

We are here
The first stakeholders meeting hosted by Imperial College was held on 10th December 2020. This was hosted using Zoom, with support from PCUK. Below is summary of the day:

"Work Package 4 team members from Imperial College London hosted a virtual Stakeholder meeting on Thursday 10th December 2020. A total of 15 stakeholders from across England attended the meeting, including clinicians specialising in pancreatic cancer, charity representatives, funding and regulatory bodies, and people affected by pancreatic cancer.

During the meeting, the EDRA team had the opportunity to present their preliminary findings, followed by a lively discussion on the potential role and point of patient access to a new blood test for the early diagnosis of pancreatic cancer. Overall, the stakeholder meeting successfully gathered valuable insights and feedback, which helped the team further understand the potential barriers to adopting the new blood test. This will also inform a future health economic model to determine the test’s cost-effectiveness if introduced to the NHS. By understanding these barriers, the process of implementing the new test to the NHS could potentially be accelerated.

Next steps...keep your eyes peeled for the upcoming Scottish Stakeholder Meeting!"

**NEWS FLASH!**

**Work Package Updates**

**WP1** – The team have completed the Q Research case-control study. We have our fingers crossed to bring you news of the publication soon!

**WP2** – Lockdown III has meant that we have been unable to access the labs but the team have been working hard remotely to continue computational modelling work.

**WP3** – The team have been working with Noclor and Rapid Diagnostic Centres to open the sample collection study to primary care patients.

**WP4** – After the success of the first stakeholder meeting, the team are preparing to host another meeting with stakeholders based in Scotland.

**EDRA Collaborators Meeting – coming soon...**

- We are planning the first EDRA Collaborators Meeting later this year. Alliance members from across the country will be invited to participate
- Keep your eyes peeled for further details and announcements!